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Summary
 
We have identified a novel Src homology 2 domain–containing leukocyte protein of 76 kD
(SLP-76)–related molecule which we have termed Clnk (for cytokine-dependent hemopoietic
cell linker). Unlike its relatives SLP-76 and B cell linker protein (Blnk), Clnk is not expressed
uniformly within a given hemopoietic cell lineage. Even though it can be detected in several
cell types, including T cells, natural killer cells, and mast cells, its expression seems to be strictly
dependent on sustained exposure to cytokines such as interleukin (IL)-2 and IL-3. Strong sup-
port for the notion that Clnk is involved in immunoreceptor signaling was provided by the ob-
servation that it inducibly associated with at least one tyrosine-phosphorylated polypeptide
(p92) in response to immunoreceptor stimulation. Moreover, transient expression of Clnk caused
an increase in immunoreceptor-mediated signaling events in a T cell line. Taken together, these
results show that Clnk is a novel member of the SLP-76 family selectively expressed in cyto-
kine-stimulated hemopoietic cells. Furthermore, they suggest that Clnk may be involved in a
cross-talk mechanism between cytokine receptor and immunoreceptor signaling.
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T
 
he Src homology 2 (SH2)
 
1
 
 domain–containing leuko-
cyte protein of 76 kD (SLP-76) family of adaptors in-
cludes two known members named SLP-76 and B linker
protein (Blnk)/SLP-65/B cell adaptor containing the SH2
domain (BASH) (1–4). Whereas SLP-76 is expressed in T
cells, NK cells, mast cells, and platelets (5), Blnk/SLP-65/
BASH is solely found in B cells (1). These two molecules
share a common structure, including from the NH
 
2
 
 to the
COOH terminus: (a) a basic region; (b) an acidic region con-
taining several sites of tyrosine phosphorylation and proline-
rich motifs able to associate with SH2 and SH3 domain–
bearing molecules, respectively; (c) an SH2 domain; and (d)
a short COOH-terminal sequence of unknown function.
Several lines of evidence demonstrate that SLP-76 plays
an essential role in T cells, platelets, and mast cells. Most
importantly, SLP-76–deficient mice were found to exhibit
a profound block in T cell maturation at a very early (dou-
ble-negative) stage, presumably due to a defect in pre-TCR
signaling (6, 7). Functional defects have also been noted in
platelets and mast cells, but not in NK cells, derived from
these animals (8, 9). Additionally, characterization of an
SLP-76–deficient variant of the T cell line Jurkat strongly
suggested that SLP-76 is necessary for TCR-induced tyro-
sine phosphorylation of phospholipase C (PLC)-
 
g
 
1, mito-
gen-activated protein (MAP) kinase activation, and IL-2
production in mature T cells (10). In a similar way, it is likely
that Blnk plays a central role in B cell development and ac-
tivation. Although Blnk-deficient mice have not yet been
described, overexpression of Blnk in B cell lines was reported
to cause an increase in B cell receptor (BCR)-induced tyro-
sine phosphorylation of PLC-
 
g
 
1 and PLC-
 
g
 
2, intracellular
calcium flux, and nuclear factor of activated T cells (NFAT)
activation (1). Conversely, a Blnk-deficient B cell line ex-
hibited dramatically reduced BCR-induced tyrosine phos-
phorylation of PLC-
 
g
 
2, intracellular calcium flux, and acti-
vation of c-Jun NH
 
2
 
-terminal kinase (JNK) (11).
Even though the exact mechanisms of action of SLP-76
and Blnk remain to be established, it is noteworthy that
SLP-76 can physically associate with several other proteins,
such as Vav, Gads, Nck, and Fyb/SLP-76–associated
phosphoprotein of 130 kD (SLAP-130) (12–19). Further-
more, Blnk can bind to Vav, PLC-
 
g
 
, Grb2, and Nck (1).
Hence, it is probable that these adaptors function by or-
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Abbreviations used in this paper:
 
 BCR, B cell antigen receptor; Blnk, B cell
linker protein; BMMC, bone marrow–derived mast cell; Clnk, cytokine-
dependent hemopoietic cell linker; Gads, Grb2-related adaptor down-
stream of Shc; NFAT, nuclear factor of activated T cells; PECAM, plate-
let-endothelial cell adhesion molecule; PLC, phospholipase C; RAH,
rabbit anti–hamster; SAM, sheep anti–mouse; SH2, Src homology 2;
SLP, SH2 domain–containing leukocyte protein of 76 kD. 
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chestrating interactions between molecules playing a criti-
cal role in immunoreceptor signaling.
In this paper, we report the cloning and characterization of
a novel molecule, which appears to represent a third member
of the SLP-76 family. Contrary to SLP-76 and Blnk, this
polypeptide is selectively expressed in cytokine-stimulated
hemopoietic cells. Based on this observation, it was termed
Clnk (for cytokine-dependent hemopoietic cell linker).
 
Materials and Methods
 
cDNA Cloning.
 
A partial 
 
clnk
 
 cDNA was initially cloned from
a mouse primitive hemopoietic cell (EML-16) cDNA library,
during a yeast two-hybrid system screen using the cytoplasmic
domain of platelet-endothelial cell adhesion molecule (PECAM)-1
as a bait (our unpublished results). Several full-length cDNAs
were subsequently isolated from a cDNA library made from day
16 fetal mouse thymus (provided by Dr. L. Matis, Alexion Phar-
maceuticals, New Haven, CT), taking the partial cDNA as a
probe. The 5
 
9
 
 end of 
 
clnk
 
 was also verified by 5
 
9
 
 rapid amplifica-
tion of cDNA ends (RACE; data not shown). Both strands of a
representative full-length cDNA clone were sequenced. The 
 
clnk
 
cDNA sequence data are available from EMBL/GenBank/DDBJ
under accession no. AF187819.
 
Cells and Tissues.
 
The various hemopoietic cell lines used
herein were described elsewhere (20–22). Splenic T cells were
isolated from 6–8-wk-old C57BL/6 mice using T cell columns
(Cytovax Biotechnologies Inc.). More than
 
 
 
90% of cells obtained
were CD3
 
1
 
 (data not shown). Splenic T cells were stimulated for
48 h with anti-CD3 mAb 145-2C11 (1 
 
m
 
g/ml [23]) immobilized
on plastic. They were then harvested, washed extensively, and re-
plated for the indicated periods of time in the absence or presence
of recombinant mouse IL-2. NK cells were obtained from splenic
tissue of 6–8-wk-old Nude CD-1 mice (Charles River Canada),
as described previously (24). Resting spleen cells were expanded for
 
z
 
8 d in growth medium containing recombinant IL-2. After this
period, nearly 100% of cells recovered were CD16
 
1
 
 and CD3
 
2
 
(data not shown). Bone marrow–derived mast cells (BMMCs)
were established from the femurs of 8-wk-old C57BL/6 mice by
prolonged culture (
 
.
 
3 wk) of bone marrow–derived cells in IL-3–
containing medium. Approximately 100% of cells obtained with
this protocol were positive for Fc
 
e
 
RI (data not shown).
 
Ribonuclease Protection Assays.
 
Ribonuclease protection assays
were performed as described elsewhere (20, 25), using a radiola-
beled antisense riboprobe corresponding to nucleotides 965–1231
of mouse 
 
clnk
 
 (sequence data available from EMBL/GenBank/
DDBJ under accession no. AF187819). The integrity of the vari-
ous RNAs used in these assays was confirmed by electrophoresis
of samples in agarose-formaldehyde gels, and subsequent staining
of the gel with ethidium bromide (data not shown).
 
Antibodies.
 
Polyclonal antibodies against Clnk were produced
by immunizing rabbits with a trpE fusion protein encompassing
amino acids 199–301 of Clnk. These antibodies did not cross-
react with SLP-76 (data not shown). Affinity purification was
achieved by passing the crude serum over a column containing
the immunogen immobilized on Affigel (Bio-Rad). Antiphos-
photyrosine mAb 4G10 was purchased from Upstate Biotechnol-
ogy. Rabbit antibodies directed against Vav have been reported
elsewhere (26).
 
Cell Stimulation.
 
The IL-2–dependent mouse T cell line 5.32.10
(22) was activated via the TCR by stimulation for 3 min at 37
 
8
 
C
in the presence of anti-CD3 mAb 145-2C11 and rabbit anti–
 
hamster (RAH) IgG. The IL-3–dependent mouse myeloid cell
line B6SutA
 
1
 
 (21) was activated via Fc
 
g
 
RI by incubation for 3 min
at 37
 
8
 
C with mouse IgG
 
2a
 
 followed by F(ab
 
9
 
)
 
2
 
 fragments of sheep
anti–mouse (SAM) IgG. After stimulation, cells were lysed in
TNE buffer (1
 
3
 
 TNE: 50 mM Tris, pH 8.0, 1% NP-40, 2 mM
EDTA), supplemented with protease and phosphatase inhibitors
as detailed elsewhere (27).
 
Immunoprecipitations and Immunoblots.
 
For immunoprecipitation,
postnuclear lysates were incubated with the indicated antibodies
for 2 h. Immune complexes were then recovered by the addition
of formalin-fixed 
 
Staphylococcus aureus
 
 (Pansorbin; Calbiochem-
Novabiochem). After several washes, proteins were eluted in
sample buffer and resolved by SDS-PAGE. For analysis of Clnk
expression, cells were lysed directly in boiling SDS-containing
sample buffer, and lysates corresponding to equivalent cell num-
bers were resolved by gel electrophoresis. Immunoblots were
done according to a previously described protocol (28), using either
 
125
 
I-labeled goat anti–mouse IgG (ICN Biomedicals) or protein
A–horseradish peroxidase and enhanced chemiluminescence re-
agents (Amersham Pharmacia Biotech).
 
Transfections.
 
For transfections, the mouse 
 
clnk
 
 and 
 
slp-76
 
 cDNAs
were individually cloned in the mammalian expression vector
pXM139, which contains the adenovirus major late promoter
and the SV40 origin of replication. Cos-1 cells were transfected
by the DEAE-dextran method with either pXM139 alone or
pXM139-
 
clnk
 
 (4 
 
m
 
g), as outlined previously (29). Jurkat TAg cells
were transfected by electroporation with pXM139 alone, pXM139-
 
clnk
 
, or pXM139-
 
slp-76
 
, in the presence of either pNFAT-luciferase,
pAP-1–luciferase, or pIL2 promoter–luciferase, according to a
protocol detailed elsewhere (15). After 40 h, 10
 
6
 
 viable cells were
stimulated for 7 h with anti-CD3 mAb OKT3 (10 
 
m
 
g/ml) alone,
OKT3 plus PMA (50 ng/ml), or PMA plus ionomycin (0.75 
 
m
 
g/
ml). Cells were then lysed and assayed for luciferase activity using
the luciferase reporter assay system (Promega) and a luminometer
(EG&G Berthold). Results are presented as percentage of luci-
ferase activity induced by PMA plus ionomycin.
 
Results
 
Identification of a cDNA Encoding a Novel SH2 Domain–
containing Molecule Related to SLP-76.
 
During an attempt
to identify new ligands for the immunoreceptor tyrosine-
based inhibitory motifs (ITIMs) of PECAM-1 (30, 31) using
the yeast two-hybrid system, we cloned a novel mouse
cDNA (see Materials and Methods). Preliminary sequence
analysis indicated that this partial cDNA encoded a new
SH2 domain–containing molecule (data not shown). Full-
length cDNA clones were subsequently obtained through
screening of a mouse thymus cDNA library and 5
 
9
 
 rapid
amplification of cDNA ends (RACE). Although we were
unable to show an association between PECAM-1 and this
novel molecule in mammalian cells (our unpublished re-
sults), its characterization was pursued as it constituted a
potentially interesting novel signal transduction molecule.
The deduced amino acid sequence of a representative
cDNA clone is shown in Fig. 1 A.
This molecule, termed Clnk (see below), is predicted to
be a 435 amino acid polypeptide. It contains, from the
NH
 
2
 
 to the COOH terminus: a basic domain, a portion
rich in tyrosines and prolines, an SH2 domain, and a
COOH-terminal tail (Fig. 1 A). BLAST (available at http:/ 
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/www.ncbi.nlm.nih.gov/BLAST/) searches showed that
the SH2 domain of Clnk is most closely related to those of
SLP-76 and Blnk (
 
z
 
40–53% identity, 
 
z
 
62–69% similarity;
references 1–4) (Fig. 1 B). This degree of homology is typical
for proteins belonging to the same family. While the over-
all structures of Clnk, SLP-76, and Blnk are also similar, it
should be pointed out that the actual sequences outside the
SH2 region of Clnk are quite distinct from those of the two
other molecules. Despite this difference, it remains likely
that Clnk represents a novel member of the SLP-76 family.
Further support for this notion will require comparison of
the exon–intron structures of the three 
 
slp-76
 
–related genes.
 
clnk Is Selectively Expressed in Cytokine-stimulated Hemopoietic
Cells.
 
The expression pattern of Clnk was analyzed by ri-
bonuclease protection assay, as detailed in Materials and
Methods (Fig. 2). Analysis of various mouse tissues (Fig. 2 A)
indicated that 
 
clnk
 
 RNA was low or undetectable in most
tissues, including bone marrow (lane 3), lymph node (lane 4),
spleen (lane 8), and thymus (lane 10). Slightly greater quan-
tities were present in kidney (lane 11). Evaluation of a
panel of mouse hemopoietic cell lines (Fig. 2 B) revealed
that most T cell (lanes 2–5), B cell (lanes 6–11), and macro-
phage (lanes 12 and 13) cell lines did not contain 
 
clnk
 
 tran-
scripts. However, a subset expressed easily appreciable amounts
of 
 
clnk
 
 RNA. These included the IL-2–dependent T cell
line HT-2 (lane 5), the IL-3–dependent pro-B cell line Ba/F3
(lane 6), the mastocytoma cell line P815 (lane 14), the IL-3–
dependent myeloid cell lines B6SutA
 
1
 
 (lane 15) and FDC-
P1 (lane 16), and the primitive leukemia cell line L1210 (lane
17). 
 
clnk
 
 was also expressed in the IL-2–dependent T cell
lines CTLL-2 (Fig. 2 C, lane 6) and 5.32.10 (lane 7), and in
the IL-3–dependent myeloid cell line 32D (lane 11). Strik-
ingly, most of the cell lines expressing 
 
clnk
 
 were dependent
on cytokines for sustained growth. On this basis, our novel
cDNA was named 
 
clnk
 
, for cytokine-dependent hemopoietic
cell linker.
The distribution of 
 
clnk
 
 was also characterized in normal
hemopoietic cells. Considering our results with the factor-
dependent cell lines, it was plausible that cytokine stimula-
tion was required to induce accumulation of 
 
clnk
 
 in these
cell types. To test this possibility, T cells were purified from
mouse spleen, and the impact of IL-2 stimulation on 
 
clnk
 
expression was evaluated. For these experiments, splenic T
cells were pretreated with anti-CD3 antibodies in order to
allow expression of functional IL-2 receptors. As expected,
resting splenic T cells (Fig. 3 A, lane 1) expressed no appre-
Figure 1. Predicted sequence and structure of Clnk. (A) The predicted
amino acid sequence of Clnk is shown. Amino acid numbering is indi-
cated on the right. The location of the SH2 domain is highlighted by a
thick continuous line. A schematic representation of the predicted struc-
ture of Clnk is depicted at the bottom. (B) Comparison of the SH2 do-
mains of mouse Clnk, mouse SLP-76, and mouse Blnk. Identical amino
acids are shown as dots.
Figure 2. Expression of clnk RNA in various mouse tissues and cell
lines. The presence of clnk transcripts in a variety of mouse tissues and cell
lines was ascertained by ribonuclease protection assay. In these assays, the
undigested riboprobe was z345 nucleotides in length, whereas the frag-
ment protected by cellular clnk transcripts was z266 nucleotides long.
End-labeled MspI-digested fragments of pBR322 were used as markers.
The positions of size markers, the undigested riboprobe, and the pro-
tected fragment of the riboprobe are indicated. Exposures: (A) 3 d; (B) 4 d;
(C) 4 d. 
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ciable amount of 
 
clnk
 
 transcripts. In a similar way, cells pre-
activated with anti-CD3 antibodies for 48 h (lane 2) did not
contain 
 
clnk
 
, even though they exhibited robust thymidine
incorporation (data not shown). However, additional stim-
ulation with exogenous IL-2 (lane 3) induced strong ex-
pression of 
 
clnk
 
, in a manner comparable to that seen in
IL-2–propagated HT-2 cells (lane 4).
Next, a time course of IL-2 stimulation was performed
(Fig. 3 B). After activation with anti-CD3 antibodies, splenic
T cells were washed extensively and replated in growth
medium with or without IL-2 for various periods of time.
In the absence of exogenous IL-2 (lanes 2 and 3), there was
a small increase in the levels of 
 
clnk
 
 RNA, which was only
visible on longer autoradiographic exposures of this gel
(data not shown). In the presence of IL-2 (lanes 4–11),
though, there was a progressive induction of 
 
clnk
 
 RNA ex-
pression. The enhancement of 
 
clnk
 
 expression could be ob-
served as early as 24 h after addition of IL-2 (lane 4), and
was maintained for at least 10 d (lane 11).
Coupled with the findings shown in Fig. 2, these data
strongly suggested that sustained IL-2 stimulation was nec-
essary for induction of 
 
clnk
 
 expression in T cells. But it was
also possible that a small subset of T cells constitutively ex-
pressing 
 
clnk
 
 expanded preferentially in the presence of IL-2.
To help resolve this issue, the impact of IL-2 on 
 
clnk
 
 ex-
pression was ascertained in an established T cell line (HT-2).
After depriving them of IL-2 for 12 h, HT-2 cells were re-
stimulated with IL-2 for various periods of time, and the
levels of 
 
clnk
 
 RNA were monitored by ribonuclease pro-
tection assay (Fig. 3 C). First, this analysis showed that re-
moval of IL-2 (lane 3) caused an approximately fourfold
reduction in the abundance of 
 
clnk
 
 RNA in HT-2 cells,
compared with cells grown in the continuous presence of
IL-2 (lane 2). Furthermore, it demonstrated that reintroduc-
tion of the cytokine (lanes 4–8) provoked a rapid increase
(approximately sixfold) in 
 
clnk
 
 expression, which was maxi-
mal after 6–9 h of stimulation (lanes 5 and 6). Thus, these ob-
servations were consistent with the idea that 
 
clnk
 
 expression in
T lymphocytes was a consequence of IL-2 stimulation.
Finally, the expression of 
 
clnk
 
 was measured in other cyto-
kine-induced normal hemopoietic cell types (Fig. 3 D). As
was the case for IL-2–stimulated splenic T cells (lane 5), we
found that 
 
clnk
 
 RNA accumulated in high amounts in IL-3–
propagated BMMCs (lane 4) and IL-2–activated NK cells
(lane 6).
 
Regulation of the Clnk Protein by Immunoreceptor Stimulation.
 
To identify the protein product of 
 
clnk
 
, a polyclonal rabbit
antiserum was generated against a bacterial fusion protein
encompassing amino acids 199–301 of Clnk. When lysates
from various hemopoietic cell lines were probed by immu-
noblotting with this antibody (Fig. 4 A), we found that
HT-2 (lane 1), CTLL-2 (lane 2), Ba/F3 (lane 3), and B6SutA
 
1
 
(lane 4), but not BI-141 T cells (lane 5), contained an
 
z
 
54-kD immunoreactive product consistent with Clnk. A
similar polypeptide was observed in Cos-1 cells transfected
with a 
 
clnk
 
 cDNA (lane 7), but not in control Cos-1 cells
(lane 6). The presence of the Clnk protein was also exam-
ined in normal hemopoietic cells (Fig. 4 B). This assay
demonstrated that IL-3–propagated BMMCs (lane 2), IL-2–
stimulated T cells (lane 3), and IL-2–activated NK cells
(lane 4) contained easily appreciable amounts of the 54-kD
Clnk protein. The nature of the additional immunoreactive
products of 
 
z
 
50 and 44 kD in 
 
clnk
 
-expressing hemopoietic
cells (lanes 2–4) remains to be determined.
To obtain evidence for the participation of Clnk in im-
munoreceptor signaling, the impact of immunoreceptor
Figure 3. Accumulation of clnk RNA in
normal mouse hemopoietic cells. The expres-
sion of clnk in normal mouse hemopoietic
cells was measured by ribonuclease protection
assay. Whereas the undigested riboprobe
contained z345 nucleotides, the fragment
protected by cellular clnk transcripts was ex-
pected to be z266 nucleotides in length.
End-labeled MspI fragments of pBR322
were used as size markers. The migrations
of size markers, the undigested riboprobe,
and the protected fragment of the riboprobe
are highlighted. (A) Induction of clnk ex-
pression by IL-2 in mouse splenic T cells.
For activation with anti-CD3 antibodies
(lane 2), cells were stimulated with plate-
bound anti-CD3 mAb 145-2C11 for 48 h.
For stimulation with IL-2 (lane 3), cells
were preactivated with anti-CD3 antibodies
as above, harvested, washed, and replated
for 5 d in growth medium supplemented
with high concentrations of recombinant
IL-2 (z50 U/ml). Exposure: 3 d. (B) Time
course of IL-2 stimulation. Cells were acti-
vated with anti-CD3 mAb as detailed in A.
After washing, they were replated for the indicated periods of time in medium containing or not recombinant IL-2. Exposure: 31 h. (C) Effects of IL-2
on clnk expression in HT-2 T cells. Cells were harvested, washed, and replated in growth medium lacking IL-2 for 12 h. IL-2 was then added for the in-
dicated periods of time, before final harvesting. Exposure: 6 h. (D) Expression of clnk in mouse BMMCs and NK cells. Cells were generated as detailed in
Materials and Methods. Exposure: 16 h.1531 Cao et al.
stimulation on its state of tyrosine phosphorylation was ex-
amined (Fig. 5). The IL-2–dependent mouse T cell line
5.32.10 was activated through the TCR by a combination of
anti-CD3 mAb 145-2C11 and RAH IgG, and the changes
in Clnk tyrosine phosphorylation were monitored by immu-
noblotting of anti-Clnk immunoprecipitates with antiphos-
photyrosine mAb 4G10 (Fig. 5 A). We found that TCR
triggering (lane 2) induced an increase in tyrosine phosphor-
ylation of a 54-kD protein (p54) consistent with Clnk. In-
terestingly, it also provoked the appearance of an z92-kD
phosphotyrosine–containing molecule (p92) in Clnk immu-
noprecipitates. Neither p54 nor p92 was present in immu-
noprecipitates generated with normal rabbit serum (NRS,
lanes 3 and 4). The regulation of Clnk was also studied in the
IL-3–dependent cell line B6SutA1, which can be activated
via its high-affinity receptor for IgG (FcgRI) by incubation
with mouse IgG2a followed by F(ab9)2 fragments of SAM
IgG (Fig. 5 B). As seen in 5.32.10 T cells, Clnk became as-
sociated with a tyrosine-phosphorylated p92 in response to
activation of B6SutA1 cells (top panel, lane 2). However, it
is noteworthy that, in contrast to 5.32.10, the Clnk protein
found in B6SutA1 was constitutively tyrosine phosphory-
lated (lane 1). While the basis for this difference is not known,
it may reflect cell type–specific variations in Clnk regulation.
Given the ability of SLP-76 and Blnk to associate with
p95vav (1, 17, 18), we wanted to determine whether the
Clnk-associated p92 represented Vav. For this purpose, paral-
lel immunoprecipitates from the experiment depicted in Fig.
5 B were probed by immunoblotting with anti-Vav antibod-
ies (Fig. 5 B, bottom panel). Even though Vav could easily be
seen in total cell lysates (lanes 5 and 6), we were unable to de-
tect any amount of Vav in Clnk immunoprecipitates (lanes 1
and 2). Thus, it seemed probable that the 92-kD tyrosine-
phosphorylated protein interacting with Clnk in response to
immunoreceptor stimulation was distinct from Vav.
Clnk Enhances Antigen Receptor–induced Activation of NFAT,
AP-1, and IL-2 Promoter in T Cells. Taking into consider-
ation its relatedness to SLP-76 and Blnk, we wished to as-
sess whether Clnk was able to impact on the outcome of
immunoreceptor signaling. For this purpose, the effect of
Clnk expression on antigen receptor–mediated activation
of NFAT, AP-1, and IL-2 promoter was evaluated (Fig. 6).
Jurkat T cells were transiently transfected by electropora-
tion with a construct encoding either Clnk or SLP-76, in
the presence of NFAT-luciferase, AP-1–luciferase, or IL-2
promoter–luciferase reporter plasmids. 40 h after transfec-
tion, cells were stimulated with anti-CD3 mAb OKT3 in
the absence or presence of the phorbol ester PMA. After
cell lysis, changes in luciferase activity were determined us-
ing a luminometer. All results were normalized according
to the luciferase activity induced by the combination of
Figure 4. Detection of the 54-kD Clnk protein in
mouse hemopoietic cells. Lysates from the indicated cells
were probed by immunoblotting with affinity-purified
rabbit anti-Clnk antibodies. It is noticeable that the elec-
trophoretic mobility of Clnk in Ba/F3 cells (A, lane 3) was
faster than that observed in the other cells. The basis for
this difference is not known. The detection of immunore-
active products at z140, 120, and 68 kD is likely due to
nonspecific cross-reactivity of the antiserum, since these
bands are also present in cells lacking clnk RNA (A, lane 5;
B, lane 1). The migrations of prestained molecular mass
markers are indicated on the right, whereas that of Clnk is
shown on the left. Exposures: (A) lanes 1–5, 1 min; lanes 6
and 7, 5 s; (B) 10 min (enhanced chemiluminescence).
Figure 5. Regulation of Clnk by immunoreceptor stimulation. (A) Ef-
fects of TCR stimulation on Clnk tyrosine phosphorylation. 5.32.10 was
grown in the presence of IL-2 and activated by anti-CD3 mAb 145-2C11
and RAH IgG. The nature of the 50-kD tyrosine-phosphorylated prod-
uct seen in anti-Clnk immunoprecipitates (lane 2) is not known. It may
represent an alternative form of Clnk protein. The migrations of p54 and
p92 are indicated on the left; those of prestained molecular mass markers
are shown on the right. Exposure: 16 h. (B) Effects of FcgRI stimulation
on Clnk tyrosine phosphorylation. B6SutA1 was propagated in medium
containing IL-3 and activated by mouse IgG2a and F(ab9)2 fragments of
SAM IgG. The identity of the 50-kD tyrosine-phosphorylated product
seen in anti-Clnk immunoprecipitates (lanes 1 and 2) is not known. It
may represent an alternative form of Clnk. The migrations of p54, p92,
and Vav are shown on the left; those of prestained molecular mass mark-
ers are indicated on the right. Exposures: top panel, 16 h; bottom panel,
30 s (enhanced chemiluminescence).1532 Clnk, a Novel SLP-76–related Adaptor
PMA and ionomycin. This experiment showed that, like
SLP-76 (18, 32, 33; Fig. 6), the Clnk protein markedly en-
hanced the activation of NFAT (Fig. 6 A), AP-1 (Fig. 6 B),
and IL-2 promoter (Fig. 6 C) in response to stimulation
with anti-CD3 antibodies. An analogous effect was seen in
cells treated with anti-CD3 plus PMA. It is of note that
both Clnk and SLP-76 were able to induce some extent of
transcriptional activation of these promoters in the absence
of CD3 stimulation. While the exact significance of this
observation is unclear, it may reflect the high levels of pro-
tein expression typically achieved in these systems.
Discussion
In this manuscript, we report the identification of a novel
SLP-76–related molecule which we have termed Clnk. At
this time, the most unique feature of Clnk is its expression
pattern. While SLP-76 is found in most, and perhaps all, T
cells, NK cells, mast cells, and myeloid cells (5), and Blnk is
seemingly contained in all B cells (1, 2, 4), the Clnk protein
is absent from most hemopoietic cells. However, significant
quantities were uncovered in IL-2–stimulated splenic T cells,
IL-2–activated NK cells, and IL-3–propagated BMMCs. In a
similar way, expression of Clnk was documented in a variety
of IL-2–dependent and IL-3–dependent cell lines. By con-
trast, it was not found in a large number of cytokine-inde-
pendent cell lines, with the exception of P815 and L1210.
Interestingly, P815 is a mastocytoma cell line carrying an ac-
tivated mutant of the Kit receptor protein tyrosine kinase
(34). Because this mutation mimics the effects of constitutive
stimulation by the Kit ligand, this finding added further cre-
dence to the notion that Clnk expression is induced after
sustained exposure to cytokines. Furthermore, it raises the
possibility that growth factors other than IL-2 and IL-3 may
have the capacity to induce Clnk expression. Future studies
should be aimed at testing this possibility.
The involvement of Clnk in immunoreceptor signaling
was first implied by the observation that it became acutely
associated with a tyrosine-phosphorylated molecule (p92) in
response to stimulation of either TCR or FcgRI. Whereas
the identity of p92 remains to be determined, it is likely
that this molecule is an effector or a regulator of Clnk. Pos-
sibly, p92 allows Clnk to become functionally active in im-
munoreceptor-stimulated cells. More definitive evidence
for the participation of Clnk in immunoreceptor-mediated
signal transduction was lent by the finding that Clnk, like
SLP-76, was capable of augmenting antigen receptor–induced
activation of NFAT, AP-1, and IL-2 promoter in transiently
transfected T cells. At first glance, this result may suggest that
Clnk and SLP-76 actually have redundant functions in hemo-
poietic cells. The presence of Clnk could explain the lack of
functional abnormalities noted in IL-2–activated NK cells
from SLP-76–deficient mice (35). Nonetheless, it should be
pointed out that Clnk and SLP-76 are likely to have special-
ized roles. Clnk lacks the two DYESP motifs present in the
NH2-terminal portion of SLP-76, which mediate binding to
the exchange factor Vav and the adaptor molecule Nck (12,
17–19, 33, 36). Accordingly, we have been unable to show
binding of Clnk to either Vav or Nck (this report; our un-
published results). Even though these interactions are not
necessary for SLP-76–mediated activation of NFAT (33, 36),
they appear to be required for proper reorganization of the
actin cytoskeleton during T cell activation (12). Likewise,
the binding motif for the Gads adaptor molecule in SLP-76
(residues 224–244 [15]) is not strictly conserved in Clnk, rais-
ing the possibility that Clnk does not associate with Gads. In-
stead, Clnk possesses other sites of tyrosine phosphorylation
and proline-rich motifs, as well as an SH2 domain, which pre-
sumably allow associations with an alternative set of partners.
One of these molecules may be p92, which was tyrosine
phosphorylated and became associated with Clnk in re-
sponse to immunoreceptor stimulation. Clearly, a better
understanding of the role of Clnk will come with the identi-
fication of these partners.
In summary, we have identified a novel SLP-76–related
adaptor molecule named Clnk. While Clnk is absent in most
hemopoietic cells, it is abundantly expressed in a variety of
hemopoietic cell types after sustained exposure to cytokines.
Taking into consideration our finding that Clnk was able to
regulate immunoreceptor signaling, these results suggest that
Clnk may provide a mechanism that modulates immunore-
ceptor signaling in response to cytokine receptor stimulation.
Figure 6. Regulation of immunoreceptor signaling by Clnk. Jurkat TAg cells were transiently transfected with the indicated DNAs (empty vector,
white bars; Clnk, black bars; SLP-76, gray bars) in the presence of NFAT- (A), AP-1– (B), or IL-2 promoter (C) luciferase reporter plasmids. 40 h after
transfection, cells were activated with the indicated stimuli for 7 h, and the changes in luciferase activity were measured as outlined in Materials and
Methods. Luciferase activity is expressed as percentage of the activity induced by PMA plus ionomycin (which represents 100%).1533 Cao et al.
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